Literature DB >> 19207640

Clinical features of 36 cases of amelanotic melanomas and considerations about the relationship between histologic subtypes and diagnostic delay.

L Gualandri1, R Betti, C Crosti.   

Abstract

BACKGROUND: Amelanotic melanomas (AM) are a difficult diagnostic challenge for clinicians.
OBJECTIVE: To consider the clinical presentation of AM, the histologic subtypes involved, the relationship with the diagnostic delay and the possible involvement in overall prognosis. PATIENTS/
METHODS: Patients who were observed in our department to be affected by cutaneous melanomas were recorded. Sex, age, the clinical features, the site of presentation, the suspected diagnosis, the clinical course, the histological type, the Clark level and the Breslow thickness were recorded. AM were divided in three main clinical types: an erythematous macule or patch on sun-exposed skin, a dermal plaque or nodule without a particular epidermal change, an exophytic nodule. Only pure AM were considered. Histological subtypes considered were superficial spreading melanoma, nodular melanoma, and lentigo maligna melanoma. Diagnostic delay considered from when the patients first noticed the lesion on the site where the melanoma was diagnosed and when the physician or the patient first proposed the removal was recorded. The chi-squared test was used for statistical evaluation with P < 0.05 as level of significance.
RESULTS: Thirty-six cases of AM out of a total of 500 melanomas (7.2%) were collected. The most frequent morphology of clinical presentation was the papulo-nodular form, followed by the plaque form. Mean Breslow thickness of AM was 1.72 mm compared to 0.61 mm of pigmented cases. Nodular histotype was highly represented in AM (30.5% of cases) with respect to pigmented nodular melanomas (2.9%). The diagnostic delay did not differ between amelanotic and pigmented melanomas, nor between nodular AM and nodular pigmented melanomas.
CONCLUSION: The great prevalence of clinical and histological nodular cases, the higher mean Breslow thickness (considered as the most important factor of prognosis) of AM compared with a not significant greater diagnostic delay may point out that a good percentage of AM have an intrinsic faster speed of growth with a worse prognosis irrespectively of the diagnostic performance. The importance of educational campaign for patient and physicians is stressed.

Entities:  

Mesh:

Year:  2008        PMID: 19207640     DOI: 10.1111/j.1468-3083.2008.03041.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  11 in total

1.  Preclinical evaluation of an 131I-labeled benzamide for targeted radiotherapy of metastatic melanoma.

Authors:  John L Joyal; John A Barrett; John C Marquis; Jianqing Chen; Shawn M Hillier; Kevin P Maresca; Marie Boyd; Kenneth Gage; Sridhar Nimmagadda; James F Kronauge; Matthias Friebe; Ludger Dinkelborg; James B Stubbs; Michael G Stabin; Rob Mairs; Martin G Pomper; John W Babich
Journal:  Cancer Res       Date:  2010-05-04       Impact factor: 12.701

2.  PET Imaging of Melanoma Using Melanin-Targeted Probe.

Authors:  Xiaowei Ma; Zhen Cheng
Journal:  Methods Mol Biol       Date:  2021

3.  Amelanotic melanomas presenting as red skin lesions: a diagnostic challenge with potentially lethal consequences.

Authors:  Susannah E McClain; Kira B Mayo; Amber L Shada; Mark E Smolkin; James W Patterson; Craig L Slingluff
Journal:  Int J Dermatol       Date:  2012-04       Impact factor: 2.736

4.  Association of Incident Amelanotic Melanoma With Phenotypic Characteristics, MC1R Status, and Prior Amelanotic Melanoma.

Authors:  Steven Vernali; Weston T Waxweiler; Patrick M Dillon; Peter A Kanetsky; Irene Orlow; Li Luo; Klaus J Busam; Anne Kricker; Bruce K Armstrong; Hoda Anton-Culver; Stephen B Gruber; Richard P Gallagher; Roberto Zanetti; Stefano Rosso; Lidia Sacchetto; Terence Dwyer; Anne E Cust; David W Ollila; Colin B Begg; Marianne Berwick; Nancy E Thomas
Journal:  JAMA Dermatol       Date:  2017-10-01       Impact factor: 10.282

5.  Risk Factors and Predictors of Survival Among Patients with Amelanotic Melanoma Compared to Melanotic Melanoma in the National Cancer Database.

Authors:  Zachary H Hopkins; Ryan P Carlisle; Zachary E Frost; Julia A Curtis; Laura K Ferris; Aaron M Secrest
Journal:  J Clin Aesthet Dermatol       Date:  2021-12

6.  Comparison of clinicopathologic features and survival of histopathologically amelanotic and pigmented melanomas: a population-based study.

Authors:  Nancy E Thomas; Anne Kricker; Weston T Waxweiler; Patrick M Dillon; Klaus J Busman; Lynn From; Pamela A Groben; Bruce K Armstrong; Hoda Anton-Culver; Stephen B Gruber; Loraine D Marrett; Richard P Gallagher; Roberto Zanetti; Stefano Rosso; Terence Dwyer; Alison Venn; Peter A Kanetsky; Irene Orlow; Susan Paine; David W Ollila; Anne S Reiner; Li Luo; Honglin Hao; Jill S Frank; Colin B Begg; Marianne Berwick
Journal:  JAMA Dermatol       Date:  2014-12       Impact factor: 10.282

7.  Cytodiagnosis of epithelioid malignant melanoma (amelanotic) and diagnostic dilemmas.

Authors:  Santosh Kumar Mondal; Palash Kumar Mondal; Sujit Kumar Dutta
Journal:  J Cytol       Date:  2014 Oct-Dec       Impact factor: 1.000

8.  Primary Anorectal Amelanotic Melanoma: The First Case Report from Saudi Arabia.

Authors:  Khaled Ali Baniyaseen; Muhammad Saeed; Ahmed Omar Albonni; Bothaina Mohammed Abdulshakour; Ghida Dairi; Faisal A Al-Allaf; Mohiuddin M Taher
Journal:  Middle East J Dig Dis       Date:  2019-05-22

9.  Amelanotic nodular melanoma misdiagnosed as a benign skin lesion: A rare case report from Syria.

Authors:  Mohammed Moutaz Alshaghel; Lana Almahairi; Roua Arian; Mohamad Shehab Alyousfi; Weaam Majanni; Rama Alyousfi; Aladdin Etr
Journal:  Ann Med Surg (Lond)       Date:  2022-01-26

10.  Amelanotic melanoma masquerading as a superficial small round cell tumor: a diagnostic challenge.

Authors:  Archana Shetty; Savitha Anil Kumar; V Geethamani; Mudasser Rehan
Journal:  Indian J Dermatol       Date:  2014-11       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.